Cargando…
Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
Passive immunotherapy with monoclonal antibodies (mAb) targeted to specific tumor-associated antigens is amongst the most rapidly expanding approaches to biological therapy of cancer. However, until now a limited number of therapeutic mAb has demonstrated clinical efficacy in selected neoplasia. Res...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC455694/ https://www.ncbi.nlm.nih.gov/pubmed/15219237 http://dx.doi.org/10.1186/1479-5876-2-21 |